

Eileen M O'reilly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6260603/publications.pdf>

Version: 2024-02-01

293
papers

19,820
citations

14644

66
h-index

13365

130
g-index

300
all docs

300
docs citations

300
times ranked

21542
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 317-327.	13.9	1,521
2	Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1028-1061.	2.3	762
3	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020, 182, 1044-1061.e18.	13.5	691
4	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	3.8	670
5	Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 851.	3.8	658
6	Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205. <i>Journal of Clinical Oncology</i> , 2010, 28, 3605-3610.	0.8	570
7	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 720-728.	13.9	520
8	Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1431.	3.4	417
9	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	0.8	397
10	Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). <i>Journal of Surgical Oncology</i> , 2008, 98, 485-489.	0.8	375
11	Intrahepatic Cholangiocarcinoma: expert consensus statement. <i>Hpb</i> , 2015, 17, 669-680.	0.1	372
12	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.	3.8	366
13	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018, 24, 4154-4161.	3.2	348
14	Tumour lineage shapes <i>BRCA</i> -mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	13.7	295
15	Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?. <i>Journal of Clinical Oncology</i> , 2010, 28, 2889-2895.	0.8	286
16	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	3.2	281
17	Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 202-210.	2.3	281
18	Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement. <i>Annals of Surgical Oncology</i> , 2009, 16, 1751-1756.	0.7	267

#	ARTICLE	IF	CITATIONS
19	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2784-2796.	0.8	267
20	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2020, 38, 1378-1388.	0.8	265
21	Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4441-4447.	0.8	254
22	Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 1313-1320.	3.2	240
23	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. <i>Oncologist</i> , 2011, 16, 1397-1402.	1.9	227
24	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
25	Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2545-2556.	0.8	204
26	Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1985-1992.	0.8	198
27	Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2398-2403.	0.8	179
28	CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2021, 22, 118-131.	5.1	177
29	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1067-1074.	3.0	170
30	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015, 121, 4382-4388.	2.0	167
31	Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. <i>BMC Cancer</i> , 2017, 17, 505.	1.1	166
32	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017, 23, 6094-6100.	3.2	161
33	Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 2157-2170.	0.8	157
34	Metastatic Pancreatic Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 3217-3230.	0.8	151
35	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3512-3521.	0.7	135
36	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , 2020, 26, 3239-3247.	3.2	135

#	ARTICLE	IF	CITATIONS
37	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 89, 19-26.	1.3	125
38	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 787-795.	0.7	124
39	A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. <i>Nature Cancer</i> , 2020, 1, 59-74.	5.7	124
40	Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy. <i>Oncologist</i> , 2011, 16, 1714-1720.	1.9	121
41	A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma. <i>Annals of Surgery</i> , 2014, 260, 142-148.	2.1	121
42	PD-1 Blockade in Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 71-80.	0.8	119
43	Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. <i>Cancer Treatment Reviews</i> , 2017, 60, 32-43.	3.4	116
44	Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. <i>World Journal of Surgical Oncology</i> , 2017, 15, 183.	0.8	112
45	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3671-3677.	0.8	112
46	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. <i>Nature Medicine</i> , 2022, 28, 1167-1177.	15.2	112
47	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2020, 38, 800-811.	1.2	106
48	Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. <i>JAMA Oncology</i> , 2021, 7, 735.	3.4	101
49	A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers. <i>PLoS ONE</i> , 2012, 7, e40157.	1.1	99
50	Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 321-325.	0.6	97
51	New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. <i>Drugs</i> , 2020, 80, 647-669.	4.9	97
52	Phase I Trial of Escalating-Dose Irinotecan Given Weekly With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2926-2932.	0.8	96
53	Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. <i>Human Pathology</i> , 2012, 43, 1677-1687.	1.1	93
54	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2018, 124, 1374-1382.	2.0	91

#	ARTICLE	IF	CITATIONS
55	Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1582.	3.4	91
56	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. <i>Gastroenterology</i> , 2016, 150, 48-63.	0.6	90
57	Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. <i>Cancer</i> , 2012, 118, 3053-3061.	2.0	85
58	Hepatocellular carcinoma in two patients with cardiac cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 889-891.	0.8	84
59	Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. <i>Cell Reports</i> , 2016, 16, 2017-2031.	2.9	84
60	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 60, 319-324.	1.8	83
61	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	0.8	83
62	A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2001, 91, 101-105.	2.0	80
63	Costs and trends in pancreatic cancer treatment. <i>Cancer</i> , 2012, 118, 5132-5139.	2.0	78
64	A Randomized Controlled Trial of a Cardiopulmonary Resuscitation Video in Advance Care Planning for Progressive Pancreas and Hepatobiliary Cancer Patients. <i>Journal of Palliative Medicine</i> , 2013, 16, 623-631.	0.6	75
65	Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. <i>Investigational New Drugs</i> , 2018, 36, 683-695.	1.2	75
66	The Evolutionary Origins of Recurrent Pancreatic Cancer. <i>Cancer Discovery</i> , 2020, 10, 792-805.	7.7	71
67	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 697-702.	2.9	70
68	The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. <i>Cancer Causes and Control</i> , 2017, 28, 959-969.	0.8	69
69	Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. <i>PLoS ONE</i> , 2017, 12, e0188022.	1.1	69
70	Pancreatic cancer—A disease in need: Optimizing and integrating supportive care. <i>Cancer</i> , 2019, 125, 3927-3935.	2.0	69
71	Failure Patterns in Resected Pancreas Adenocarcinoma. <i>Annals of Surgery</i> , 2013, 258, 331-335.	2.1	68
72	Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. <i>BMC Cancer</i> , 2018, 18, 693.	1.1	68

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 41.	1.3	68
74	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	5.8	68
75	Augmenting advance care planning in poor prognosis cancer with a video decision aid. <i>Cancer</i> , 2012, 118, 4331-4338.	2.0	66
76	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	0.8	66
77	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. <i>Annals of Surgical Oncology</i> , 2002, 9, 954-960.	0.7	65
78	Cytotoxic Therapy for Advanced Pancreatic Adenocarcinoma. <i>Seminars in Oncology</i> , 2007, 34, 347-353.	0.8	63
79	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1277.	3.8	63
80	Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer. <i>Pancreas</i> , 2016, 45, 986-991.	0.5	61
81	A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. <i>Cancer</i> , 2017, 123, 4556-4565.	2.0	61
82	A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. <i>Cancer Medicine</i> , 2019, 8, 5148-5157.	1.3	60
83	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. <i>Cancer Discovery</i> , 2022, 12, 1233-1247.	7.7	60
84	Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 378-378.	0.8	59
85	A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603). <i>Oncologist</i> , 2010, 15, 1310-1319.	1.9	58
86	Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2803-2815.	0.8	58
87	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	1.8	53
88	Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease. <i>Annals of Surgical Oncology</i> , 2012, 19, 1663-1669.	0.7	52
89	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	5.1	51
90	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631.	0.8	51

#	ARTICLE	IF	CITATIONS
91	Phase II trial of sequential paclitaxel and 1Âh infusion of bryostatin-1 in patients with advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 875-880.	1.1	50
92	Prognosis of Minimally Invasive Carcinoma Arising in Mucinous Cystic Neoplasms of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 601-605.	2.1	50
93	Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 3-9.	0.8	50
94	Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5281-5289.	3.2	49
95	Secondâ€line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. <i>Cancer</i> , 2019, 125, 4426-4434.	2.0	49
96	Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7014-7023.	3.2	47
97	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2020, 126, 3939-3949.	2.0	44
98	Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. , 2019, , .		44
99	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 50-58.	2.3	41
100	Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. <i>Clinical Cancer Research</i> , 2019, 25, 2185-2193.	3.2	41
101	Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2020, 33, 1822-1831.	2.9	40
102	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1-13.	1.4	39
103	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. <i>Acta OncolÃ³gica</i> , 2017, 56, 1746-1753.	0.8	38
104	A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. <i>Pancreatology</i> , 2009, 9, 404-409.	0.5	37
105	Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. <i>BMC Cancer</i> , 2018, 18, 769.	1.1	37
106	Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. <i>Annals of Oncology</i> , 2019, 30, 1959-1968.	0.6	37
107	A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 429-440.	1.1	35
108	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1194-1202.	3.0	35

#	ARTICLE	IF	CITATIONS
109	An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice. <i>JAMA Oncology</i> , 2020, 6, 764.	3.4	35
110	DNA Mismatch Repair Abnormalities in Acinar Cell Carcinoma of the Pancreas. <i>Pancreas</i> , 2014, 43, 1264-1270.	0.5	34
111	Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 341-359.	1.5	34
112	Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. <i>Cancer</i> , 2019, 125, 575-585.	2.0	34
113	Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?. <i>Clinical Cancer Research</i> , 2018, 24, 2241-2250.	3.2	32
114	Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. <i>Cancer Treatment Reviews</i> , 2019, 75, 27-38.	3.4	32
115	Pancreatic adenocarcinoma in a young patient population—12-year experience at Memorial Sloan Kettering Cancer Center. <i>Journal of Surgical Oncology</i> , 2009, 100, 8-12.	0.8	31
116	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. <i>Oncologist</i> , 2017, 22, 1429-e139.	1.9	31
117	Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications. <i>Clinical Colorectal Cancer</i> , 2016, 15, 360-368.	1.0	30
118	Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 78-85.	1.1	30
119	Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2021, 156, 663.	2.2	30
120	A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma. <i>Cancer Investigation</i> , 1999, 17, 195-200.	0.6	29
121	A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4672-TPS4672.	0.8	29
122	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	28
123	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. <i>Cancer</i> , 2019, 125, 1441-1448.	2.0	28
124	A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 217-217.	0.8	28
125	Biliary tract cancers: current concepts and controversies. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 211-223.	0.9	27
126	Acquired resistance to immunotherapy in MMR-D pancreatic cancer. , 2018, 6, 127.		27

#	ARTICLE	IF	CITATIONS
127	Refinement of Adjuvant Therapy for Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2010, 304, 1124.	3.8	26
128	90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. European Journal of Cancer, 2015, 51, 1857-1864.	1.3	26
129	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. Cancer, 2020, 126, 1995-2002.	2.0	26
130	Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers. , 2019, , .		26
131	ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. Journal of Oncology Practice, 2016, 12, 151-152.	2.5	25
132	Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection*. Acta Oncologica, 2017, 56, 384-390.	0.8	24
133	A Randomized Trial of Acceptability and Effects of Values-Based Advance Care Planning in Outpatient Oncology: Person-Centered Oncologic Care and Choices. Journal of Pain and Symptom Management, 2018, 56, 169-177.e1.	0.6	24
134	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncology, 2020, 6, 1713.	3.4	24
135	Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. BMC Cancer, 2021, 21, 385.	1.1	24
136	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	2.0	24
137	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of the National Cancer Institute, 2022, 114, 427-435.	3.0	24
138	Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. Journal of Neuro-Oncology, 2012, 106, 15-21.	1.4	23
139	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clinical Colorectal Cancer, 2015, 14, 269-276.e1.	1.0	23
140	Phase II Trial of 96-Hour Paclitaxel in Previously Treated Patients with Advanced Esophageal Cancer. Cancer Investigation, 2003, 21, 512-516.	0.6	22
141	Lymph Node Metastasis Predicts Disease Recurrence in a Single-Center Experience of 70 Stages 1-3 Appendix Cancers: A Retrospective Review. Annals of Surgical Oncology, 2015, 22, 3613-3617.	0.7	22
142	Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. Clinical Cancer Research, 2019, 25, 937-945.	3.2	22
143	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectrum, 2020, 4, pkz078.	1.4	22
144	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. European Journal of Cancer, 2020, 132, 112-121.	1.3	22

#	ARTICLE	IF	CITATIONS
145	Pain and Emotional Well-Being Outcomes in Southwest Oncology Groupâ€‘Directed Intergroup Trial S0205: A Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine As First-Line Therapy in Patients With Advanced Pancreas Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3611-3616.	0.8	21
146	Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2018, 17, 121-128.	1.0	21
147	Targeted Agents and Systemic Therapy in Hepatocellular Carcinoma. <i>Recent Results in Cancer Research</i> , 2013, 190, 225-246.	1.8	21
148	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a preâ€‘specified subgroup analysis of the randomized CASSINI study. <i>Cancer Medicine</i> , 2020, 9, 6196-6204.	1.3	20
149	Treatment patterns and survival in patients with earlyâ€‘onset pancreatic cancer. <i>Cancer</i> , 2021, 127, 3566-3578.	2.0	20
150	Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 835-846.	2.3	19
151	Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 311-326.	0.6	19
152	Perioperative Gemcitabineâ€‘+â€‘Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 4489-4497.	0.7	19
153	Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?. <i>Journal of Clinical Oncology</i> , 2020, 38, 1757-1759.	0.8	19
154	Non-Hodgkin Lymphoma as a Cause of Intrahepatic Periportal Low Attenuation on CT. <i>Journal of Computer Assisted Tomography</i> , 1997, 21, 726-728.	0.5	19
155	Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). <i>Cancer</i> , 2012, 118, 571-578.	2.0	18
156	A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. <i>Pancreatology</i> , 2014, 14, 398-402.	0.5	18
157	Current management and future directions in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2016, 122, 3765-3775.	2.0	18
158	Development of an advance care planning paradigm for advanced cancer: person-centered oncologic care and choices (P-COCC). <i>Psycho-Oncology</i> , 2017, 26, 866-869.	1.0	18
159	Targeting DNA damage repair pathways in pancreas cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 891-908.	2.7	18
160	Adjuvant and Neoadjuvant Systemic Therapy for Pancreas Adenocarcinoma. <i>Seminars in Oncology</i> , 2015, 42, 134-143.	0.8	17
161	A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020, 25, 925-e1603.	1.9	17
162	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4023-4023.	0.8	17

#	ARTICLE	IF	CITATIONS
163	Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).. Journal of Clinical Oncology, 2017, 35, 343-343.	0.8	17
164	Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Appendiceal Mucinous Neoplasms With Isolated Peritoneal Metastasis. Diseases of the Colon and Rectum, 2012, 55, 407-415.	0.7	16
165	Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?. World Journal of Surgical Oncology, 2013, 11, 131.	0.8	16
166	Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. Hpb, 2019, 21, 1541-1551.	0.1	16
167	Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology, 2017, 35, 279-279.	0.8	16
168	Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 783-791.e1.	2.3	16
169	Novel Therapeutics for Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 777-787.	0.9	15
170	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Annals of Surgery, 2021, 274, 894-901.	2.1	15
171	Liver resection for metastatic colorectal leiomyosarcoma: a single center experience. Journal of Gastrointestinal Oncology, 2015, 6, E70-6.	0.6	15
172	Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. Journal of Gastrointestinal Oncology, 2016, 7, 738-749.	0.6	14
173	Ablative Radiotherapy Doses for Locally Advanced. Cancer Journal (Sudbury, Mass), 2017, 23, 350-354.	1.0	14
174	Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precision Oncology, 2021, 5, 1325-1338.	1.5	14
175	Pancreas adenocarcinoma: novel therapeutics. Chinese Clinical Oncology, 2017, 6, 30-30.	0.4	14
176	Building on Individual, State, and Federal Initiatives for Advance Care Planning, an Integral Component of Palliative and End-of-Life Cancer Care. Journal of Oncology Practice, 2011, 7, 355-359.	2.5	13
177	Postresection Surveillance for Pancreatic Cancer Performance Status, Imaging, and Serum Markers. Cancer Journal (Sudbury, Mass), 2012, 18, 609-613.	1.0	13
178	Adjuvant therapy for pancreas adenocarcinoma. Journal of Surgical Oncology, 2013, 107, 78-85.	0.8	13
179	Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma—An Infrequent Event: Elucidation of Risk Factors and Management Implications. Clinical Colorectal Cancer, 2016, 15, 24-31.	1.0	13
180	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype—Phenotype Features—An Entity With an Increasing Incidence?. Clinical Colorectal Cancer, 2018, 17, e315-e321.	1.0	13

#	ARTICLE	IF	CITATIONS
181	A 67-Year-Old Woman with BRCA 1 Mutation Associated with Pancreatic Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 160-164.	0.6	12
182	Electronic Chemotherapy Order Entry: A Major Cancer Center's Implementation. <i>Journal of Oncology Practice</i> , 2011, 7, 213-218.	2.5	12
183	Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 467.	1.7	12
184	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1.	0.6	12
185	Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. <i>Cancer Medicine</i> , 2020, 9, 7453-7459.	1.3	11
186	Pancreas cancer: Therapeutic trials in metastatic disease. <i>Journal of Surgical Oncology</i> , 2021, 123, 1475-1488.	0.8	11
187	Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. <i>Communications Biology</i> , 2021, 4, 1333.	2.0	11
188	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	3.2	11
189	A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 334-339.	0.6	10
190	Collision Tumor of the Large Bowel in the Context of Advanced Pregnancy and Ulcerative Colitis. <i>Clinical Colorectal Cancer</i> , 2008, 7, 402-405.	1.0	10
191	New Approaches to the Treatment of Pancreatic Cancer. <i>BioDrugs</i> , 2011, 25, 207-216.	2.2	10
192	Sunitinib malate for the treatment of pancreas malignancies – where does it fit?. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 783-792.	0.9	10
193	Management of Metastatic Pancreatic Adenocarcinoma. <i>Surgical Clinics of North America</i> , 2016, 96, 1391-1414.	0.5	10
194	Duration of therapy for locally advanced pancreatic cancer: Does it matter?. <i>Cancer Medicine</i> , 2020, 9, 4572-4580.	1.3	10
195	Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. <i>Clinical Colorectal Cancer</i> , 2018, 17, e207-e216.	1.0	9
196	Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2021, 127, 1568-1575.	2.0	9
197	NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4661-TPS4661.	0.8	9
198	Understanding Pancreatic Diseases Using Animated Pancreas Patient. <i>Pancreas</i> , 2018, 47, 1256-1261.	0.5	8

#	ARTICLE	IF	CITATIONS
199	Liver and Bile Duct Cancer. , 2020, , 1314-1341.e11.		8
200	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2020, 4, pkaa024.	1.4	8
201	Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Network Open, 2020, 3, e2023500.	2.8	8
202	Pancreatic ductal adenocarcinoma in the era of precision medicine. Seminars in Oncology, 2021, 48, 19-33.	0.8	8
203	Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology, 2015, 33, 278-278.	0.8	8
204	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.. Journal of Clinical Oncology, 2019, 37, 4016-4016.	0.8	8
205	Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine-Related Cancer, 2022, 29, 335-344.	1.6	8
206	Emerging therapies for pancreas neuroendocrine cancers. Chinese Clinical Oncology, 2013, 2, 23.	0.4	8
207	Adjuvant therapy for pancreas adenocarcinoma: where are we going?. Expert Review of Anticancer Therapy, 2011, 11, 173-177.	1.1	7
208	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. Cancer, 2021, 127, 4585-4593.	2.0	7
209	A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma. Gastrointestinal Cancer Research: GCR, 2012, 5, 185-9.	0.8	7
210	Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review. European Journal of Gastroenterology and Hepatology, 2010, 22, 246-252.	0.8	6
211	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	1.4	6
212	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer. , 2001, 8, 787.		6
213	Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Journal of Surgical Oncology, 2022, 125, 425-436.	0.8	6
214	Indications for Neoadjuvant, Adjuvant, and Palliative Chemotherapy in the Treatment of Biliary Tract Cancers. Surgical Oncology Clinics of North America, 2009, 18, 361-379.	0.6	5
215	A mixed methods analysis of patients'™ advance care planning values in outpatient oncology: Person-Centered Oncologic Care and Choices (P-COCC). Supportive Care in Cancer, 2020, 28, 1109-1119.	1.0	5
216	Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes. Cancer Medicine, 2020, 9, 8480-8490.	1.3	5

#	ARTICLE	IF	CITATIONS
217	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. <i>Cancer</i> , 2020, 126, 4126-4135.	2.0	5
218	Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 220-220.	0.8	5
219	Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 370-370.	0.8	5
220	Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 774-774.	0.8	5
221	Liver and Bile Duct Cancer. , 2014, , 1373-1396.e8.		5
222	Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes. <i>Cancer Medicine</i> , 2023, 12, 179-188.	1.3	5
223	Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. <i>Investigational New Drugs</i> , 2009, 27, 366-373.	1.2	4
224	Evolving Panorama of Treatment for Metastatic Pancreas Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1621-1623.	0.8	4
225	Texture analysis for survival prediction of pancreatic ductal adenocarcinoma patients with neoadjuvant chemotherapy. , 2016, , .		4
226	Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, E65-E72.	0.6	4
227	A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 79-86.	1.1	4
228	Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. <i>Abdominal Radiology</i> , 2021, 46, 1607-1617.	1.0	4
229	Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity. <i>Pancreatology</i> , 2021, 21, 599-605.	0.5	4
230	Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 298-298.	0.8	4
231	Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4102-4102.	0.8	4
232	Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe ^a , in patients with pancreatic cancer and other CA19-9 positive malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4110-4110.	0.8	4
233	Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 405-405.	0.8	4
234	A Review of Pancreatic Cancer”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2436.	3.8	4

#	ARTICLE	IF	CITATIONS
235	Pathologic Complete Response to Neoadjuvant FOLFOX in Combination with Bevacizumab in Unresectable Metastatic Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2008, 7, 140-143.	1.0	3
236	Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreatic cancer. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 312-313.	4.3	3
237	Synchronous Epithelial and Neuroendocrine Cancers of the Pancreas: Case Series of a Rare Occurrence. <i>Clinical Colorectal Cancer</i> , 2011, 10, 146-150.	1.0	3
238	MicroRNA, hypoxic stress and hepatocellular carcinoma: Future directions. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1586-1588.	1.4	3
239	Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 585-601.	1.4	3
240	Classification of Pancreatic Cancer: Ready for Practical Application?. <i>Clinical Cancer Research</i> , 2018, 24, 4355-4356.	3.2	3
241	BRCA1/2 (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies. <i>Chinese Clinical Oncology</i> , 2020, 9, 64-64.	0.4	3
242	Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4114-4114.	0.8	3
243	Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 437-437.	0.8	3
244	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 648-648.	0.8	3
245	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. , 2002, 9, 954.		3
246	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. <i>Journal of Geriatric Oncology</i> , 2022, 13, 469-479.	0.5	3
247	Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.. <i>Journal of Clinical Oncology</i> , 2022, 40, 528-528.	0.8	3
248	Gastrointestinal Cancer Educational Case Series: Management of Metastatic Adenocarcinoma of Unknown Primary Origin in a Ph+ ALL Survivor. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 165-170.	0.6	2
249	A Man with Klinefelter's Syndrome and New Abdominal Distension: A Discussion of Evaluation and Management. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 314-318.	0.6	2
250	Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 358-358.	0.8	2
251	Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15791-e15791.	0.8	2
252	Accomplishments in 2008 in the management of localized pancreatic cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, S37-42.	0.8	2

#	ARTICLE	IF	CITATIONS
253	Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 130-4.	0.8	2
254	A woman with metastatic pancreatic neuroendocrine tumor. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 27-32.	0.8	2
255	Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. <i>Cancer</i> , 2022, 128, 2958-2966.	2.0	2
256	Concurrent Germline <i>BRCA1</i> and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options. <i>JCO Precision Oncology</i> , 2022, , .	1.5	2
257	Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4186-TPS4186.	0.8	2
258	Precision Medicine and Immunotherapy in GI Cancers. <i>Journal of Clinical Oncology</i> , 2022, 40, 2659-2661.	0.8	2
259	Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors. <i>Cancer Investigation</i> , 2009, 27, 402-406.	0.6	1
260	Capsule-Induced Small-Bowel Obstruction During Video Capsule Endoscopy in a Patient with Carcinomatosis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1778-1780.	1.1	1
261	A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 236-240.	0.6	1
262	Gastrointestinal Cancer Educatinal Case Series: A 65 year-old Female with Locally Advanced Gastric Cancer and a Supraclavicular Lymph Node. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 93-96.	0.6	1
263	Reply to N. Fazio. <i>Journal of Clinical Oncology</i> , 2020, 38, 2467-2468.	0.8	1
264	Liver and Bile Duct Cancer. , 2008, , 1569-1594.		1
265	Abstract IA28: BRCA-mutated pancreas adenocarcinoma: Emerging therapeutic implications. , 2015, , .		1
266	A novel scoring system to predict survival in patients with advanced pancreatic adenocarcinoma: The Memorial Prognostic Score (MPS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 36-36.	0.8	1
267	Acceptability and effects of values-based outpatient advance care planning (ACP) in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9-9.	0.8	1
268	Multimodality therapy in metastatic pancreas cancer with a <i>BRCA</i> mutation and durable long-term outcome: biology, intervention, or both?. <i>Cancer Biology and Therapy</i> , 2021, 22, 532-536.	1.5	1
269	Liver-directed conversion therapy in metastatic colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 322-8.	0.6	1
270	Neoadjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	1

#	ARTICLE	IF	CITATIONS
271	Venous Thromboprophylaxis in Surgical Oncology Patients: The Importance of Risk Assessment in the Context of Limited Evidence. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102935.	0.8	1
272	Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
273	Lack of Splenic Uptake of In-111 Pentetreotide Due to Splenic Embolization. <i>Clinical Nuclear Medicine</i> , 2009, 34, 960-961.	0.7	0
274	Targeting thrombosis in exocrine pancreas cancer: a continued need for improved therapies. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1783-1785.	1.1	0
275	FOLFIRINOX induction therapy for stage III pancreatic adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2014, 219, e176.	0.2	0
276	Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma. <i>Journal of Oncology Practice</i> , 2016, 12, 31-32.	2.5	0
277	An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 596-602.	0.6	0
278	Reply to G.W. Peters et al and S. Shi et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2947-2948.	0.8	0
279	Reply to Nutritional support in pancreatic cancer. <i>Cancer</i> , 2020, 126, 1811-1812.	2.0	0
280	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10-10.	0.8	0
281	Targeted Therapies for Hepatocellular Carcinoma. , 2011, , 355-368.		0
282	Identification of germline genetic mutations in patients with pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 159-159.	0.8	0
283	Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance.. <i>Journal of Clinical Oncology</i> , 2013, 31, 142-142.	0.8	0
284	Abstract B98: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies. , 2015, , .		0
285	Preface: pancreas adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 23-23.	0.4	0
286	Synthetic Lethality: Achilles Heel in Select Patient Subpopulations. , 2018, , 257-270.		0
287	Preface for Special Edition Pancreas Cancer. <i>Chinese Clinical Oncology</i> , 2017, 6, 57-57.	0.4	0
288	Nano-liposomal irinotecan and 5-FU/LV (N+F) for the treatment of advanced PDAC: Memorial Sloan Kettering (MSK) Single Cancer Center Evaluation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 471-471.	0.8	0

#	ARTICLE	IF	CITATIONS
289	Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers.. Journal of Clinical Oncology, 2020, 38, 4620-4620.	0.8	0
290	Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Gastrointestinal Cancer Research: GCR, 2013, 6, 115-7.	0.8	0
291	"This is not me": patient, family, cultural and clinician considerations in cases of severe cancer-related debility. Journal of Gastrointestinal Oncology, 2015, 6, 589-93.	0.6	0
292	Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective. , 2021, , 221-255.		0
293	Precision Approaches to Pancreatic Cancer Therapy: What Now and What Next?. Current Treatment Options in Gastroenterology, 0, , .	0.3	0